Cannabis Use and the Risk for Psychosis and Affective Disorders

References

• Aas, M., Etain, B., Bellivier, F., Henry, C., Lagerberg, T., Ringen, A., … Melle, I. (2014). Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. Psychological Medicine, 44(8), 1653–1662. doi:10.1017/S0033291713002316
   PubMed Web of Science ®Google Scholar
• Agrawal, A., Nelson, E. C., Bucholz, K. K., Tillman, R., Grucza, R. A., Statham, D. J., … Lynskey, M. T. (2017). Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: A retrospective cohort study. The Lancet Psychiatry, 4(9), 706–714. doi:10.1016/S2215-0366(17)30280-8
   PubMed Web of Science ®Google Scholar
• Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. The Lancet, 330(8574), 1483–1486. doi:10.1016/S0140-6736(87)92620-1
   Web of Science ®Google Scholar
• Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. British Medical Journal, 325(7374), 1212–1213. doi:10.1136/bmj.325.7374.1212
   PubMed Web of Science ®Google Scholar
• Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between cannabis and psychosis: Examination of the evidence. The British Journal of Psychiatry, 184(2), 110–117. doi:10.1192/bjp.184.2.110
   PubMed Web of Science ®Google Scholar
• Ashton, C. H., & Moore, P. B. (2011). Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatrica Scandinavica, 124(4), 250–261. doi:10.1111/j.1600-0447.2011.01687.x
   PubMed Web of Science ®Google Scholar
• Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19(3), 293–300. doi:10.1177/0269881105051541
   PubMed Web of Science ®Google Scholar
• Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241–254. doi:10.1177/2045125312457586
   PubMedGoogle Scholar
• Baethge, C., Hennen, J., Khalsa, H. M. K., Salvatore, P., Tohen, M., & Baldessarini, R. J. (2008). Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disorders, 10(6), 738–741. doi:10.1111/j.1399-5618.2007.00575.x
   PubMed Web of Science ®Google Scholar
• Baggio, S., N’Goran, A. A., Deline, S., Studer, J., Dupuis, M., Henchoz, Y., … Gmel, G. (2014). Patterns of cannabis use and prospective associations with health issues among young males. Addiction, 109(6), 937–945. doi:10.1111/add.12490
   PubMed Web of Science ®Google Scholar
• Bahorik, A. L., Leibowitz, A., Sterling, S. A., Travis, A., Weisner, C., & Satre, D. D. (2017). Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. Journal of Affective Disorders, 213, 168–171. doi:10.1016/j.jad.2017.02.016
   PubMed Web of Science ®Google Scholar
• Balenga, N. A. B., Henstridge, C. M., Kargl, J., & Waldhoer, M. (2011). Pharmacology, signaling and physiological relevance of the G Protein-coupled Receptor 55. Advances in Pharmacology, 62, 251–277. doi:10.1016/B978-0-12-385952-5.00004-X
   PubMedGoogle Scholar
• Bambico, F. R., Nguyen, N. T., Katz, N., Gobbi, G. (2010). Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. Neurobiology of Disease, 37(3), 641–655. doi:10.1016/j.nbd.2009.11.020
   PubMed Web of Science ®Google Scholar
• Baskin-Sommers, A. R., & Foti, D. (2015). Abnormal reward functioning across substance use disorders and major depressive disorder: Considering reward as a transdiagnostic mechanism. International Journal of Psychophysiology, 98(2), 227–239. doi:10.1016/j.ijpsycho.2015.01.011
   PubMed Web of Science ®Google Scholar
• Battistella, G., Fornari, E., Annoni, J.-M., Chtioui, H., Dao, K., Fabritius, M., … Giroud, C. (2014). Long-term effects of cannabis on brain structure. Neuropsychopharmacology, 39(9), 2041–2048. doi:10.1038/npp.2014.67
   PubMed Web of Science ®Google Scholar
• Berenson, A. (2019). Tell your children: The truth about marijuana, mental illness, and violence. New York, NY: Free Press.
   Google Scholar
• Berridge, K. C., Robinson, T. E., & Aldridge, J. W. (2009). Dissecting components of reward: ‘Liking’, ‘wanting’, and learning. Current Opinion in Pharmacology, 9(1), 65–73. doi:10.1016/j.coph.2008.12.014
   PubMed Web of Science ®Google Scholar
• Bianconi, F., Bonomo, M., Marconi, A., Kolliakou, A., Stilo, S. A., Iyegbe, C., … Di Forti, M. (2016). Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychological Medicine, 46(5), 995–1003. doi:10.1017/S0033291715002494
   PubMed Web of Science ®Google Scholar
• Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., … Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134(4), 845–852. doi:10.1038/sj.bjp.0704327
   PubMed Web of Science ®Google Scholar
• Bloomfield, M. A. P., Morgan, C. J. A., Egerton, A., Kapur, S., Curran, H. V., & Howes, O. D. (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biological Psychiatry, 75(6), 470–478. doi:10.1016/j.biopsych.2013.05.027
   PubMed Web of Science ®Google Scholar
• Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2018). Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology, 43(1), 142–154. doi:10.1038/npp.2017.209
   PubMed Web of Science ®Google Scholar
• Borges, G., Bagge, C. L., & Orozco, R. (2016). A literature review and meta-analyses of cannabis use and suicidality. Journal of Affective Disorders, 195, 63–74. doi:10.1016/j.jad.2016.02.007
   PubMed Web of Science ®Google Scholar
• Boydell, J., Van Os, J., Caspi, A., Kennedy, N., Giouroukou, P., Fearon, P., … Murray, R. M. (2006). Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychological Medicine, 36(10), 1441–1446. doi:10.1017/S0033291706008440
   PubMed Web of Science ®Google Scholar
• Brook, J. S., Rosen, Z., & Brook, D. W. (2001). The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist, 13(1), 35–40.
   Google Scholar
• Brown, A. J. (2007). Novel cannabinoid receptors. British Journal of Pharmacology, 152(5), 567–575. doi:10.1038/sj.bjp.0707481
   PubMed Web of Science ®Google Scholar
• Brunette, M. F., Dawson, R., O’Keefe, C. D., Narasimhan, M., Noordsy, D. L., Wojcik, J., & Green, A. I. (2011). A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of Dual Diagnosis, 7(1–2), 50–63. doi:10.1080/15504263.2011.570118
   PubMed Web of Science ®Google Scholar
• Buckner, J. D., Schmidt, N. B., Lang, A. R., Small, J. W., Schlauch, R. C., & Lewinsohn, P. M. (2008). Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. Journal of Psychiatric Research, 42(3), 230–239. doi:10.1016/j.jpsychires.2007.01.002
   PubMed Web of Science ®Google Scholar
• Budney, A. J., Roffman, R., Stephens, R. S., & Walker, D. (2007). Marijuana dependence and its treatment. Addiction Science & Clinical Practice, 4(1), 4–16. doi:10.1151/ASCP07414
   PubMedGoogle Scholar
• Cairns, K. E., Yap, M. B. H., Pilkington, P. D., & Jorm, A. F. (2014, December). Risk and protective factors for depression that adolescents can modify: A systematic review and meta-analysis of longitudinal studies. Journal of Affective Disorders, 169, 61–75. doi:10.1016/j.jad.2014.08.006
   PubMed Web of Science ®Google Scholar
• Campos, A. C., & Guimarães, F. S. (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology, 199(2), 223–230. doi:10.1007/s00213-008-1168-x
   PubMed Web of Science ®Google Scholar
• Carney, R., Cotter, J., Firth, J., Bradshaw, T., & Yung, A. R. (2017). Cannabis use and symptom severity in individuals at ultra high risk for psychosis: A meta‐analysis. Acta Psychiatrica Scandinavica, 136(1), 5–15. doi:10.1111/acps.12699
   PubMed Web of Science ®Google Scholar
• Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., … Craig, I. W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: Longitudinal evidence of a gene x environment interaction. Biological Psychiatry, 57(10), 1117–1127. doi:10.1016/j.biopsych.2005.01.026
   PubMed Web of Science ®Google Scholar
• Ceccarini, J., Kuepper, R., Kemels, D., Van Os, J., Henquet, C., & Van Laere, K. (2015). [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addiction Biology, 20(2), 357–367. doi:10.1111/adb.12116
   PubMed Web of Science ®Google Scholar
• Cerdá, M. (2017). Commentary: Does early cannabis initiation reduce educational attainment? New contributions and unanswered questions. International Journal of Epidemiology, 46(5), 1650–1652. doi:10.1093/ije/dyx162
   PubMed Web of Science ®Google Scholar
• Chadwick, B., Miller, M. L., & Hurd, Y. L. (2013). Cannabis use during adolescent development: Susceptibility to psychiatric illness. Frontiers in Psychiatry, 4, 129. doi:10.3389/fpsyt.2013.00129
   PubMedGoogle Scholar
• Coentre, R., Talina, M. C., Góis, C., & Figueira, M. L. (2017). Depressive symptoms and suicidal behavior after first-episode psychosis: A comprehensive systematic review. Psychiatry Research, 253, 240–248. doi:10.1016/j.psychres.2017.04.010
   PubMed Web of Science ®Google Scholar
• Colizzi, M., Iyegbe, C., Powell, J., Blasi, G., Bertolino, A., Murray, R. M., & Di Forti, M. (2015). Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: A case–control study. NPJ Schizophrenia, 1(1), 15025. doi:10.1038/npjschz.2015.25
   PubMedGoogle Scholar
• Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Frontiers in Immunology, 9(21), 2009. doi:10.3389/fimmu.2018.02009
   PubMedGoogle Scholar
• Crippa, J. A., Zuardi, A. W., Martín-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: A critical review of the evidence. Human Psychopharmacology, 24(7), 515–523. doi:10.1002/hup.1048
   PubMed Web of Science ®Google Scholar
• D’Souza, D. C., Cortes-Briones, J. A., Ranganathan, M., Thurnauer, H., Creatura, G., Surti, T., … Skosnik, P. D. (2016). Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 1(1), 60–67. doi:10.1016/j.bpsc.2015.09.008
   Google Scholar
• Daniel, J. Z., Hickman, M., Macleod, J., Wiles, N., Lingford-Hughes, A., Farrell, M., … Lewis, G. (2009). Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug and Alcohol Review, 28(2), 142–153. doi:10.1111/j.1465-3362.2008.00042.x
   PubMed Web of Science ®Google Scholar
• Danielsson, A. K., Lundin, A., Agardh, E., Allebeck, P., & Forsell, Y. (2016). Cannabis use, depression and anxiety: A 3-year prospective population-based study. Journal of Affective Disorders, 193, 103–108. doi:10.1016/j.jad.2015.12.045
   PubMed Web of Science ®Google Scholar
• De Luca, M. A., Di Chiara, G., Cadoni, C., Lecca, D., Orsolini, L., Papanti, D., … Schifano, F. (2017). Cannabis; epidemiological, neurobiological and psychopathological issues: An update. CNS & Neurological Disorders - Drug Targets, 16(5), 598–609. doi:10.2174/1871527316666170413113246
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Hall, W., & Lynskey, M. (2003). Exploring the association between cannabis use and depression. Addiction, 98(11), 1493–1504. doi:10.1046/j.1360-0443.2003.00437.x
   PubMed Web of Science ®Google Scholar
• Deng, H., Verrico, C. D., Kosten, T. R., & Nielsen, D. A. (2018). Psychosis and synthetic cannabinoids. Psychiatry Research, 268, 400–412. doi:10.1016/j.psychres.2018.08.012
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Iyegbe, C., Sallis, H., Kolliakou, A., Falcone, M., Paparelli, A., … Murray, R. M. (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry, 72(10), 811–816. doi:10.1016/j.biopsych.2012.06.020
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., … Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet Psychiatry, 2(3), 233–238. doi:10.1016/S2215-0366(14)00117-5
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., … Murray, R. M. (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry, 195(6), 488–491. doi:10.1192/bjp.bp.109.064220
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., … van der Ven, E. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. The Lancet Psychiatry, 6(5), 427–436. doi:10.1016/S2215-0366(19)30048-3
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Vassos, E., Lynskey, M., Craig, M., & Murray, R. M. (2015). Cannabis and psychosis – authors’ reply. The Lancet Psychiatry, 2(5), 382. doi:10.1016/S2215-0366(15)00177-7
   PubMed Web of Science ®Google Scholar
• Duperrouzel, J., Hawes, S. W., Lopez-Quintero, C., Pacheco-Colón, I., Comer, J., & Gonzalez, R. (2018). The association between adolescent cannabis use and anxiety: A parallel process analysis. Addictive Behaviors, 78, 107–113. doi:10.1016/j.addbeh.2017.11.005
   PubMed Web of Science ®Google Scholar
• ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. Biological Psychiatry, 79(7), 613–619. doi:10.1016/j.biopsych.2016.01.004
   PubMed Web of Science ®Google Scholar
• Englund, A., Atakan, Z., Kralj, A., Tunstall, N., Murray, R., & Morrison, P. (2016). The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. Journal of Psychopharmacology, 30(2), 140–151. doi:10.1177/0269881115615104
   PubMed Web of Science ®Google Scholar
• Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., … Kapur, S. (2012). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology, 27(1), 19–27. doi:10.1177/0269881112460109
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. (2016). European Drug Report 2016: Trends and Developments. European Union, Luxembourg. doi:10.2810/04312
   Google Scholar
• Fattore, L., & Fratta, W. (2010). How important are sex differences in cannabinoid action. British Journal of Pharmacology, 160(3), 544–548. doi:10.1111/j.1476-5381.2010.00776.x
   PubMed Web of Science ®Google Scholar
• Fawley, J. A., Hofmann, M. E., & Andresen, M. C. (2014). Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission. The Journal of Neuroscience, 34(24), 8324–8332. doi:10.1523/JNEUROSCI.0315-14.2014
   PubMed Web of Science ®Google Scholar
• Feingold, D., Rehm, J., Factor, H., Redler, A., & Lev-Ran, S. (2018). Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3-year population-based longitudinal study. Depression and Anxiety, 35(6), 490–501. doi:10.1002/da.22735
   PubMed Web of Science ®Google Scholar
• Feingold, D., Rehm, J., & Lev-Ran, S. (2017). Cannabis use and the course and outcome of major depressive disorder: A population based longitudinal study. Psychiatry Research, 251, 225–234. doi:10.1016/j.psychres.2017.02.027
   PubMed Web of Science ®Google Scholar
• Feingold, D., Weiser, M., Rehm, J., & Lev-Ran, S. (2015). The association between cannabis use and mood disorders: A longitudinal study. Journal of Affective Disorders, 172, 211–218. doi:10.1016/j.jad.2014.10.006
   PubMed Web of Science ®Google Scholar
• Feingold, D., Weiser, M., Rehm, J., & Lev-Ran, S. (2016). The association between cannabis use and anxiety disorders: Results from a population-based representative sample. European Neuropsychopharmacology, 26(3), 493–505. doi:10.1016/j.euroneuro.2015.12.037
   PubMed Web of Science ®Google Scholar
• Fergusson, D. M., Horwood, L. J., & Ridder, E. M. (2005). Tests of causal linkages between cannabis use and psychotic symptoms. Addiction, 100(3), 354–366. doi:10.1111/j.1360-0443.2005.01001.x
   PubMed Web of Science ®Google Scholar
• Ferraro, L., La Cascia, C., Quattrone, D., Sideli, L., Matranga, D., Capuccio, V., … & Sham, P. (2019). Premorbid adjustment and IQ in patients with first-episode psychosis: A multisite case-control study of their relationship with cannabis use. Schizophrenia Bulletin. doi:10.1093/schbul/sbz077
   Google Scholar
• Ferraro, L., Russo, M., O’Connor, J., Wiffen, B. D. R., Falcone, M. A., Sideli, L., … Di Forti, M. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophrenia Research, 150(1), 129–135. doi:10.1016/j.schres.2013.07.046
   PubMed Web of Science ®Google Scholar
• Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014). Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and previous stressful experience. European Neuropsychopharmacology, 24(3), 410–419. doi:10.1016/j.euroneuro.2013.10.012
   PubMed Web of Science ®Google Scholar
• Freeman, T. P., & Winstock, A. R. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychological Medicine, 45(15), 3181–3189. doi:10.1017/S0033291715001178
   PubMed Web of Science ®Google Scholar
• French, L., Gray, C., Leonard, G., Perron, M., Pike, G. B., Richer, L., … Paus, T. (2015). Early cannabis use, polygenic risk score for schizophrenia, and brain maturation in adolescence. JAMA Psychiatry, 72(10), 1002–1011. doi:10.1001/jamapsychiatry.2015.1131
   PubMed Web of Science ®Google Scholar
• Gage, S. H., Hickman, M., Heron, J., Munafò, M. R., Lewis, G., Macleod, J., & Zammit, S. (2015). Associations of cannabis and cigarette use with depression and anxiety at age 18: Findings from the Avon Longitudinal Study of Parents and Children. PLoS ONE, 10(4), e0122896. doi:10.1371/journal.pone.0122896
   PubMed Web of Science ®Google Scholar
• Gage, S. H., Hickman, M., & Zammit, S. (2016). Association between cannabis and psychosis: Epidemiologic evidence. Biological Psychiatry, 79(7), 549–556. doi:10.1016/j.biopsych.2015.08.001
   PubMed Web of Science ®Google Scholar
• Gage, S. H., Jones, H. J., Burgess, S., Bowden, J., Davey Smith, G., Zammit, S., & Munafò, M. R. (2017). Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychological Medicine, 47(5), 971–980. doi:10.1017/S0033291716003172
   PubMed Web of Science ®Google Scholar
• Gage, S. H., Munafò, M. R., MacLeod, J., Hickman, M., & Smith, G. D. (2015). Cannabis and psychosis. The Lancet Psychiatry, 2(5), 380. doi:10.1016/S2215-0366(15)00108-X
   PubMed Web of Science ®Google Scholar
• Gibbs, M., Winsper, C., Marwaha, S., Gilbert, E., Broome, M., & Singh, S. P. (2014). Cannabis use and mania symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 171, 39–47. doi:10.1016/j.jad.2014.09.016
   PubMed Web of Science ®Google Scholar
• Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., … Mayo, N. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis. JAMA Psychiatry, 76(4), 426–434. doi:10.1001/jamapsychiatry.2018.4500
   PubMed Web of Science ®Google Scholar
• Gruber, S. A., Dahlgren, M. K., Sagar, K. A., Gönenç, A., & Lukas, S. E. (2014). Worth the wait: Effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology, 231(8), 1455–1465. doi:10.1007/s00213-013-3326-z
   PubMed Web of Science ®Google Scholar
• Guloksuz, S., Pries, L., Delespaul, P., Kenis, G., Luykx, J. J., Lin, B. D., … van Os, J. (2019). Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: Results from the EUGEI study. World Psychiatry, 18(2), 173–182. doi:10.1002/wps.20629
   PubMed Web of Science ®Google Scholar
• Gurillo, P., Jauhar, S., Murray, R. M., & MacCabe, J. H. (2015). Does tobacco use cause psychosis? Systematic review and meta-analysis. The Lancet Psychiatry, 2(8), 718–725. doi:10.1016/S2215-0366(15)00152-2
   PubMed Web of Science ®Google Scholar
• Guttmannova, K., Kosterman, R., White, H. R., Bailey, J. A., Lee, J. O., Epstein, M., … Hawkins, J. D. (2017). The association between regular marijuana use and adult mental health outcomes. Drug and Alcohol Dependence, 179, 109–116. doi:10.1016/j.drugalcdep.2017.06.016
   PubMed Web of Science ®Google Scholar
• Hanna, R. C., Perez, J. M., & Ghose, S. (2017). Cannabis and development of dual diagnoses: A literature review. The American Journal of Drug and Alcohol Abuse, 43(4), 442–455. doi:10.1080/00952990.2016.1213273
   PubMed Web of Science ®Google Scholar
• Hanuš, L. O. (2009). Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Medicinal Research Reviews, 29(2), 213–271. doi:10.1002/med.20135
   PubMed Web of Science ®Google Scholar
• Hardwick Leslie, S. K. (2008). Home Office Cannabis Potency Study 2008. St Albans, UK: Home Office Scientific Brance.
   Google Scholar
• Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., … Grant, B. F. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12), 1235–1242. doi:10.1001/jamapsychiatry.2015.1858
   PubMed Web of Science ®Google Scholar
• Henquet, C., Krabbendam, L., de Graaf, R., ten Have, M., & van Os, J. (2006). Cannabis use and expression of mania in the general population. Journal of Affective Disorders, 95(1–3), 103–110. doi:10.1016/j.jad.2006.05.002
   PubMed Web of Science ®Google Scholar
• Henstridge, C. M., Balenga, N. A. B., Kargl, J., Andradas, C., Brown, A. J., Irving, A., … Waldhoer, M. (2011). Minireview: Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Molecular Endocrinology, 25(11), 1835–1848. doi:10.1210/me.2011-1197
   PubMedGoogle Scholar
• Hill, S., Shanahan, L., Costello, E. J., & Copeland, W. (2017). Predicting persistent, limited, and delayed problematic cannabis use in early adulthood: Findings from a longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 56(11), 966–974.e4. doi:10.1016/j.jaac.2017.08.012
   PubMed Web of Science ®Google Scholar
• Hindocha, C., Freeman, T. P., Ferris, J. A., Lynskey, M. T., & Winstock, A. R. (2016). No smoke without tobacco: A global overview of cannabis and tobacco routes of administration and their association with intention to quit. Frontiers in Psychiatry, 7, 104. doi:10.3389/fpsyt.2016.00104
   PubMed Web of Science ®Google Scholar
• Hindocha, C., Freeman, T. P., Xia, J. X., Shaban, N. D. C., & Curran, H. V. (2017). Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’ and individually: A placebo-controlled trial. Psychological Medicine, 47(15), 2708–2719. doi:10.1017/S0033291717001222
   PubMed Web of Science ®Google Scholar
• Hindocha, C., Shaban, N. D. C., Freeman, T. P., Das, R. K., Gale, G., Schafer, G., … Curran, H. V. (2015). Associations between cigarette smoking and cannabis dependence: A longitudinal study of young cannabis users in the United Kingdom. Drug and Alcohol Dependence, 148, 165–171. doi:10.1016/j.drugalcdep.2015.01.004
   PubMed Web of Science ®Google Scholar
• Hirvonen, J., Goodwin, R. S., Li, C. T., Terry, G. E., Zoghbi, S. S., Morse, C., … Innis, R. B. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6), 642–649. doi:10.1038/mp.2011.82
   PubMed Web of Science ®Google Scholar
• Hjorthoj, C. R., Baker, A., Fohlmann, A., & Nordentoft, M. (2014). Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis. Current Pharmaceutical Design, 20(13), 2205–2211. doi:10.2174/13816128113199990431
   PubMed Web of Science ®Google Scholar
• Horwood, L. J., Fergusson, D. M., Coffey, C., Patton, G. C., Tait, R., Smart, D., … Hutchinson, D. M. (2012). Cannabis and depression: An integrative data analysis of four Australasian cohorts. Drug and Alcohol Dependence, 126(3), 369–378. doi:10.1016/j.drugalcdep.2012.06.002
   PubMed Web of Science ®Google Scholar
• Hosseini, S., & Oremus, M. (2018). The effect of age of initiation of cannabis use on psychosis, depression, and anxiety among youth under 25 years. The Canadian Journal of Psychiatry, 64, 304–312. doi:10.1177/0706743718809339
   PubMed Web of Science ®Google Scholar
• Howlett, A. C., Bidaut-Russell, M., Devane, W. A., Melvin, L. S., Johnson, M. R., & Herkenham, M. (1990). The cannabinoid receptor: Biochemical, anatomical and behavioral characterization. Trends in Neurosciences, 13(10), 420–423. doi:10.1016/0166-2236(90)90124-S
   PubMed Web of Science ®Google Scholar
• Hser, Y. I., Mooney, L. J., Huang, D., Zhu, Y., Tomko, R. L., McClure, E., … Gray, K. M. (2017). Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. Journal of Substance Abuse Treatment, 81, 53–58. doi:10.1016/j.jsat.2017.07.012
   PubMed Web of Science ®Google Scholar
• Jones, H. J., Gage, S. H., Heron, J., Hickman, M., Lewis, G., Munafo, M. R., & Zammit, S. (2018). Association of combined patterns of tobacco and cannabis use in adolescence with psychotic experiences. JAMA Psychiatry, 75(3), 240–246. doi:10.1001/jamapsychiatry.2017.4271
   PubMed Web of Science ®Google Scholar
• Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology, 372(5), 354–361. doi:10.1007/s00210-006-0033-x
   PubMed Web of Science ®Google Scholar
• Katona, I., & Freund, T. F. (2012). Multiple functions of endocannabinoid signaling in the brain. Annual Review of Neuroscience, 35(1), 529–558. doi:10.1146/annurev-neuro-062111-150420
   PubMedGoogle Scholar
• Kedzior, K. K., & Laeber, L. T. (2014). A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies. BMC Psychiatry, 14(1), 136. doi:10.1186/1471-244X-14-136
   PubMedGoogle Scholar
• Kim, S. W., Dodd, S., Berk, L., Kulkarni, J., De Castella, A., Fitzgerald, P. B., … Berk, M. (2015). Impact of cannabis use on long-term remission in bipolar I and schizoaffective disorder. Psychiatry investigation, 12(3), 349–355. doi:10.4306/pi.2015.12.3.349
   PubMed Web of Science ®Google Scholar
• Klosterkötter, J., Hellmich, M., Gerth, C. W., Muhl, D., Koethe, D., Leweke, F. M., … Hoyer, C. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94. doi:10.1038/tp.2012.15
   PubMed Web of Science ®Google Scholar
• Kraan, T., Velthorst, E., Koenders, L., Zwaart, K., Ising, H. K., van den Berg, D., … & van der Gaag, M. (2016). Cannabis use and transition to psychosis in individuals at ultra-high risk: Review and meta-analysis. Psychological Medicine, 46(4), 673–681. doi:10.1017/S0033291715002329
   PubMed Web of Science ®Google Scholar
• Kvitland, L. R., Melle, I., Aminoff, S. R., Demmo, C., Lagerberg, T. V., Andreassen, O. A., & Ringen, P. A. (2015). Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder. BMC Psychiatry, 15(1), 11. doi:10.1186/s12888-015-0389-x
   PubMedGoogle Scholar
• Large, M., Sharma, S., Compton, M. T., Slade, T., & Nielssen, O. (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Archives of General Psychiatry, 68(6), 555–561. doi:10.1001/archgenpsychiatry.2011.5
   PubMed Web of Science ®Google Scholar
• Lawn, W., Freeman, T. P., Pope, R. A., Joye, A., Harvey, L., Hindocha, C., … Curran, H. V. (2016). Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: An evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology, 233(19–20), 3537–3552. doi:10.1007/s00213-016-4383-x
   PubMed Web of Science ®Google Scholar
• Leite, R. T. P., Nogueira, Sde O., do Nascimento, J. P. R., de Lima, L. S., da Nóbrega, T. B., Virgínio, M. da S., … de Matos E Souza, F. G. (2015). The use of cannabis as a predictor of early onset of bipolar disorder and suicide attempts. Neural Plasticity, 2015, 434127. doi:10.1155/2015/434127
   PubMed Web of Science ®Google Scholar
• Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44(4), 797–810. doi:10.1017/S0033291713001438
   PubMed Web of Science ®Google Scholar
• Lowe, D. J. E., Sasiadek, J. D., Coles, A. S., & George, T. P. (2019). Cannabis and mental illness: A review. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 107–120. doi:10.1007/s00406-018-0970-7
   PubMed Web of Science ®Google Scholar
• Mammen, G., Rueda, S., Roerecke, M., Bonato, S., Lev-Ran, S., & Rehm, J. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: A systematic review of prospective studies. Journal of Clinical Psychiatry, 79(4). doi:10.4088/JCP.17r11839
   PubMed Web of Science ®Google Scholar
• Manrique-Garcia, E., Zammit, S., Dalman, C., Hemmingsson, T., Andreasson, S., & Allebeck, P. (2011). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychological Medicine, 42(6), 1321–1328. doi:10.1017/S0033291711002078
   PubMed Web of Science ®Google Scholar
• Marangoni, C., Hernandez, M., & Faedda, G. L. (2016). The role of environmental exposures as risk factors for bipolar disorder: A systematic review of longitudinal studies. Journal of Affective Disorders, 193, 165–174. doi:10.1016/j.jad.2015.12.055
   PubMed Web of Science ®Google Scholar
• Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. doi:10.1093/schbul/sbw003
   PubMed Web of Science ®Google Scholar
• Marwaha, S., Winsper, C., Bebbington, P., & Smith, D. (2018). Cannabis use and hypomania in young people: A prospective analysis. Schizophrenia Bulletin, 44(6), 1267–1274. doi:10.1093/schbul/sbx158
   PubMed Web of Science ®Google Scholar
• Mathew, R., Turkington, T., Hawk, T., Coleman, R. E., & Provenzale, J. (2000). Brain morphological changes and early marijuana use. Journal of Addictive Diseases, 19(1), 1–22. doi:10.1300/J069v19n01_01
   PubMed Web of Science ®Google Scholar
• McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., … Wright, S. (2017). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225–231. doi:10.1176/appi.ajp.2017.17030325
   PubMed Web of Science ®Google Scholar
• McLaren, J. A., Silins, E., Hutchinson, D., Mattick, R. P., & Hall, W. (2010). Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. International Journal of Drug Policy, 21(1), 10–19. doi:10.1016/j.drugpo.2009.09.001
   PubMed Web of Science ®Google Scholar
• McLoughlin, B. C., Pushpa-Rajah, J. A., Gillies, D., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014). Cannabis and schizophrenia. Cochrane Database of Systematic Review, 14(10), CD004837. doi:10.1002/14651858.CD004837.pub3
   Google Scholar
• McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015). Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 172(3), 737–753. doi:10.1111/bph.12944
   PubMed Web of Science ®Google Scholar
• Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64(1), 21–47. doi:10.1146/annurev-psych-113011-143739
   PubMed Web of Science ®Google Scholar
• Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370(9584), 319–328. doi:10.1016/S0140-6736(07)61162-3
   PubMed Web of Science ®Google Scholar
• Morales, P., Goya, P., Jagerovic, N., & Hernandez-Folgado, L. (2016). Allosteric modulators of the CB 1 cannabinoid receptor: A structural update review. Cannabis and Cannabinoid Research, 1(1), 22–30. doi:10.1089/can.2015.0005
   PubMedGoogle Scholar
• Morgan, C. J. A., & Curran, H. V. (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. British Journal of Psychiatry, 192(4), 306–307. doi:10.1192/bjp.bp.107.046649
   PubMed Web of Science ®Google Scholar
• Morgan, C. J. A., Freeman, T. P., Powell, J., & Curran, H. V. (2016). AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Translational Psychiatry, 6, e738. doi:10.1038/tp.2015.219
   PubMed Web of Science ®Google Scholar
• Murray, R. M., Englund, A., Abi-Dargham, A., Lewis, D. A., Di Forti, M., Davies, C., … D’Souza, D. C. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104. doi:10.1016/j.neuropharm.2017.06.018
   PubMed Web of Science ®Google Scholar
• Murray, R. M., & Lewis, S. W. (1987). Is schizophrenia a neurodevelopmental disorder? British Medical Journal (Clinical Research Ed.), 295(6600), 681–682. doi:10.1136/bmj.295.6600.681
   PubMed Web of Science ®Google Scholar
• Murray, R. M., Quigley, H., Quattrone, D., Englund, A., & Di Forti, M. (2016). Traditional marijuana, high-potency cannabis and synthetic cannabinoids: Increasing risk for psychosis. World Psychiatry, 15(3), 195–204. doi:10.1002/wps.20341
   PubMed Web of Science ®Google Scholar
• Mustonen, A., Ahokas, T., Nordström, T., Murray, G. K., Mäki, P., Jääskeläinen, E., … Niemelä, S. (2018). Smokin‘hot: Adolescent smoking and the risk of psychosis. Acta Psychiatrica Scandinavica, 138(1), 5–14. doi:10.1111/acps.12863
   PubMed Web of Science ®Google Scholar
• Myles, H., Myles, N., & Large, M. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Australian & New Zealand Journal of Psychiatry, 50(3), 208–219. doi:10.1177/0004867415599846
   PubMed Web of Science ®Google Scholar
• Nelemans, S. A., Hale, W. W., Raaijmakers, Q. A. W., Branje, S. J. T., van Lier, P. A. C., & Meeus, W. H. J. (2016). Longitudinal associations between social anxiety symptoms and cannabis use throughout adolescence: The role of peer involvement. European Child & Adolescent Psychiatry, 25(5), 483–492. doi:10.1007/s00787-015-0747-8
   PubMed Web of Science ®Google Scholar
• Otten, R., & Engels, R. C. M. E. (2013). Testing bidirectional effects between cannabis use and depressive symptoms: Moderation by the serotonin transporter gene. Addiction Biology, 18(5), 826–835. doi:10.1111/j.1369-1600.2011.00380.x
   PubMed Web of Science ®Google Scholar
• Otten, R., Huizink, A. C., Monshouwer, K., Creemers, H. E., & Onrust, S. (2017). Cannabis use and symptoms of anxiety in adolescence and the moderating effect of the serotonin transporter gene. Addiction Biology, 22(4), 1081–1089. doi:10.1111/adb.12372
   PubMed Web of Science ®Google Scholar
• Page, M. E., Oropeza, V. C., Sparks, S. E., Qian, Y., Menko, A. S., & Van Bockstaele, E. J. (2007). Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacology Biochemistry and Behavior, 86(1), 162–168. doi:10.1016/j.pbb.2006.12.020
   PubMed Web of Science ®Google Scholar
• Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., … Bonavigo, T. (2013). “Spiceophrenia”: A systematic overview of “Spice”-related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental, 28(4), 379–389. doi:10.1002/hup.2312
   PubMed Web of Science ®Google Scholar
• Pasman, J. A., Verweij, K. J. H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J. L., … International Cannabis, C. (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nature Neuroscience, 21(9), 1161–1170. doi:10.1038/s41593-018-0206-1
   PubMed Web of Science ®Google Scholar
• Pertwee, R. G. (2005). Pharmacological actions of cannabinoids. Handbook of Experimental Pharmacology, 168, 1–51.
   Google Scholar
• Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. doi:10.1038/sj.bjp.0707442
   PubMed Web of Science ®Google Scholar
• Pijlman, F. T. A., Rigter, S. M., Hoek, J., Goldschmidt, H. M. J., & Niesink, R. J. M. (2005). Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology, 10(2), 171–180. doi:10.1080/13556210500123217
   PubMed Web of Science ®Google Scholar
• Pinto, J. V., Medeiros, L. S., Santana da Rosa, G., Santana de Oliveira, C. E., Crippa, J. A. de S., Passos, I. C., & Kauer-Sant’Anna, M. (2019). The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. Neuroscience & Biobehavioral Reviews, 101, 78–84. doi:10.1016/j.neubiorev.2019.04.004
   PubMed Web of Science ®Google Scholar
• Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4(11), 873–884. doi:10.1038/nrn1247
   PubMed Web of Science ®Google Scholar
• Pollard, M. S., Tucker, J. S., Green, H. D., de la Haye, K., & Espelage, D. L. (2018). Adolescent peer networks and the moderating role of depressive symptoms on developmental trajectories of cannabis use. Addictive Behaviors, 76, 34–40. doi:10.1016/j.addbeh.2017.07.019
   PubMed Web of Science ®Google Scholar
• Power, R. A., Verweij, K. J. H., Zuhair, M., Montgomery, G. W., Henders, A. K., Heath, A. C., … Martin, N. G. (2014). Genetic predisposition to schizophrenia associated with increased use of cannabis. Molecular Psychiatry, 19(11), 1201–1204. doi:10.1038/mp.2014.51
   PubMed Web of Science ®Google Scholar
• Rhew, I. C., Fleming, C. B., Vander Stoep, A., Nicodimos, S., Zheng, C., & McCauley, E. (2017). Examination of cumulative effects of early adolescent depression on cannabis and alcohol use disorder in late adolescence in a community-based cohort. Addiction, 112(11), 1952–1960. doi:10.1111/add.13907
   PubMed Web of Science ®Google Scholar
• Rottanburg, D., Ben-Arie, O., Robins, A. H., Teggin, A., & Elk, R. (1982). Cannabis-associated psychosis with hypomanic features. The Lancet, 320(8312), 1364–1366. doi:10.1016/S0140-6736(82)91270-3
   Google Scholar
• Ruiz-Veguilla, M., F. Callado, L., & Ferrin, M. (2012). Neurological soft signs in patients with psychosis and cannabis abuse: A systematic review and meta-analysis of paradox. Current Pharmaceutical Design, 18(32), 5156–5164. doi:10.2174/138161212802884753
   PubMed Web of Science ®Google Scholar
• Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., … Bhattacharyya, S. (2016). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. The Lancet Psychiatry, 3(3), 215–225. doi:10.1016/S2215-0366(15)00363-6
   PubMed Web of Science ®Google Scholar
• Schoeler, T., Theobald, D., Pingault, J.-B., Farrington, D. P., Coid, J. W., & Bhattacharyya, S. (2018). Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: Findings from 40 years of follow-up. Psychological Medicine, 48(13), 2169–2176. doi:10.1017/S0033291717003658
   PubMed Web of Science ®Google Scholar
• Schubart, C. D., Sommer, I. E. C., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., & Boks, M. P. M. (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research, 130(1–3), 216–221. doi:10.1016/j.schres.2011.04.017
   PubMed Web of Science ®Google Scholar
• Silins, E., Horwood, L. J., Patton, G. C., Fergusson, D. M., Olsson, C. A., Hutchinson, D. M., … Mattick, R. P. (2014). Young adult sequelae of adolescent cannabis use: An integrative analysis. The Lancet Psychiatry, 1(4), 286–293. doi:10.1016/S2215-0366(14)70307-4
   PubMed Web of Science ®Google Scholar
• Stapinski, L. A., Montgomery, A. A., & Araya, R. (2016). Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents. Drug and Alcohol Dependence, 166, 109–115. doi:10.1016/j.drugalcdep.2016.06.032
   PubMed Web of Science ®Google Scholar
• Starowicz, K., Cristino, L., & Di Marzo, V. (2008). TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Current Pharmaceutical Design, 14(1), 42–54. doi:10.2174/138161208783330790
   PubMed Web of Science ®Google Scholar
• Strakowski, S. M., DelBello, M. P., Fleck, D. E., Adler, C. M., Anthenelli, R. M., Keck, P. E., … Amicone, J. (2007). Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry, 64(1), 57–64. doi:10.1001/archpsyc.64.1.57
   PubMed Web of Science ®Google Scholar
• Swift, W., Wong, A., Li, K. M., Arnold, J. C., & McGregor, I. S. (2013). Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PLoS ONE, 8(7), e70052. doi:10.1371/journal.pone.0070052
   PubMed Web of Science ®Google Scholar
• Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016). A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology, 54(1), 1–13. doi:10.3109/15563650.2015.1110590
   PubMed Web of Science ®Google Scholar
• Twomey, C. D. (2017). Association of cannabis use with the development of elevated anxiety symptoms in the general population: A meta-analysis. Journal of Epidemiology and Community Health, 71(8), 811–816. doi:10.1136/jech-2016-208145
   PubMed Web of Science ®Google Scholar
• Tzavara, E. T., Li, D. L., Moutsimilli, L., Bisogno, T., Di Marzo, V., Phebus, L. A., … Giros, B. (2006). Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: Therapeutic implications. Biological Psychiatry, 59(6), 508–515. doi:10.1016/j.biopsych.2005.08.019
   PubMed Web of Science ®Google Scholar
• Urban, N. B. L., Slifstein, M., Thompson, J. L., Xu, X., Girgis, R. R., Raheja, S., … Abi-Dargham, A. (2012). Dopamine release in chronic cannabis users: A [11c]raclopride positron emission tomography study. Biological Psychiatry, 71(8), 677–683. doi:10.1016/j.biopsych.2011.12.018
   PubMed Web of Science ®Google Scholar
• Vaessen, T. S. J., De Jong, L., Schäfer, A. T., Damen, T., Uittenboogaard, A., Krolinski, P., … Drukker, M. (2018). The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: A transdiagnostic meta-analysis. PLoS ONE, 13(2), e0192658. doi:10.1371/journal.pone.0192658
   PubMed Web of Science ®Google Scholar
• Van Der Kooy, F., Pomahacova, B., & Verpoorte, R. (2008). Cannabis smoke condensate I: The effect of different preparation methods on tetrahydrocannabinol levels. Inhalation Toxicology, 20(9), 801–804. doi:10.1080/08958370802013559
   PubMed Web of Science ®Google Scholar
• van Hell, H. H., Jager, G., Bossong, M. G., Brouwer, A., Jansma, J. M., Zuurman, L., … Ramsey, N. F. (2012). Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology, 219(4), 981–990. doi:10.1007/s00213-011-2428-8
   PubMed Web of Science ®Google Scholar
• Van Laar, M., Van Dorsselaer, S., Monshouwer, K., & De Graaf, R. (2007). Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction, 102(8), 1251–1260. doi:10.1111/j.1360-0443.2007.01875.x
   PubMed Web of Science ®Google Scholar
• Van Rossum, I., Boomsma, M., Tenback, D., Reed, C., & Van Os, J. (2009). Does cannabis use affect treatment outcome in bipolar disorder?: A longitudinal analysis. Journal of Nervous and Mental Disease, 197(1), 35–40. doi:10.1097/NMD.0b013e31819292a6
   PubMed Web of Science ®Google Scholar
• van Winkel, R., van Beveren, N. J. M., Simons, C., Kahn, R. S. S., Linszen, D. H., van Os, J., … de Haan, L. (2011). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology, 36(12), 2529–2537. doi:10.1038/npp.2011.141
   PubMed Web of Science ®Google Scholar
• Vaucher, J., Keating, B. J., Lasserre, A. M., Gan, W., Lyall, D. M., Ward, J., … Holmes, M. V. (2018). Cannabis use and risk of schizophrenia: A Mendelian randomization study. Molecular Psychiatry, 23(5), 1287–1292. doi:10.1038/mp.2016.252
   PubMed Web of Science ®Google Scholar
• Verweij, K. J. H., Abdellaoui, A., Nivard, M. G., Sainz Cort, A., Ligthart, L., Draisma, H. H. M., … Vink, J. M. (2017). Short communication: Genetic association between schizophrenia and cannabis use. Drug and Alcohol Dependence, 171, 117–121. doi:10.1016/j.drugalcdep.2016.09.022
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227. doi:10.1056/NEJMra1402309
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Hampson, A. J., & Baler, R. D. (2017). Don’t worry, be happy: Endocannabinoids and cannabis at the intersection of stress and reward. Annual Review of Pharmacology and Toxicology, 57(1), 285–308. doi:10.1146/annurev-pharmtox-010716-104615
   PubMedGoogle Scholar
• Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Alexoff, D., Logan, J., … Tomasi, D. (2014). Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proceedings of the National Academy of Sciences of the United States of America, 111(30), E3149–E3156. doi:10.1073/pnas.1411228111
   PubMed Web of Science ®Google Scholar
• Weinstein, A. M., Rosca, P., Fattore, L., & London, E. D. (2017). Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Frontiers in Psychiatry, 8, 156. doi:10.3389/fpsyt.2017.00156
   PubMed Web of Science ®Google Scholar
• White, C. M. (2019). A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. Journal of Clinical Pharmacology, 59(7), 923–934. doi:10.1002/jcph.1387
   PubMed Web of Science ®Google Scholar
• Wittchen, H.-U., Fröhlich, C., Behrendt, S., Günther, A., Rehm, J., Zimmermann, P., … Perkonigg, A. (2007). Cannabis use and cannabis use disorders and their relationship to mental disorders: A 10-year prospective-longitudinal community study in adolescents. Drug and Alcohol Dependence, 88 (Suppl 1), S60–S70. doi:10.1016/j.drugalcdep.2006.12.013
   PubMedGoogle Scholar
• Womack, S. R., Shaw, D. S., Weaver, C. M., & Forbes, E. E. (2016). Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men. Journal of Studies on Alcohol and Drugs, 77(2), 287–297. doi:10.15288/jsad.2016.77.287
   PubMed Web of Science ®Google Scholar
• Wycoff, A. M., Metrik, J., & Trull, T. J. (2018). Affect and cannabis use in daily life: A review and recommendations for future research. Drug and Alcohol Dependence, 191, 223–233. doi:10.1016/j.drugalcdep.2018.07.001
   PubMed Web of Science ®Google Scholar
• Yücel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S. M., … Pantelis, C. (2010). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia bulletin, 38(2), 316–330. doi:10.1093/schbul/sbq079
   PubMed Web of Science ®Google Scholar
• Zammit, S. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ, 325(7374), 1199–1199. doi:10.1136/bmj.325.7374.1199
   PubMed Web of Science ®Google Scholar
• Zammit, S., Moore, T. H., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. The British Journal of Psychiatry, 193(5), 357–363. doi:10.1192/bjp.bp.107.046375
   PubMed Web of Science ®Google Scholar
• Zorrilla, I., Aguado, J., Haro, J. M., Barbeito, S., López Zurbano, S., Ortiz, A., … Gonzalez-Pinto, A. (2015). Cannabis and bipolar disorder: Does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatrica Scandinavica, 131(2), 100–110. doi:10.1111/acps.12366
   PubMed Web of Science ®Google Scholar